Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Journal of Gastrointestinal Cancer
Erschienen in:

27.02.2024 | Review

The Prognostic Importance of Ki-67 in Gastrointestinal Carcinomas: A Meta-analysis and Multi-omics Approach

verfasst von: Mahdieh Razmi, Fatemeh Tajik, Farideh Hashemi, Ayna Yazdanpanah, Fatemeh Hashemi-Niasari, Adeleh Divsalar

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to determine if Ki-67, a commonly used marker to measure tumor proliferation, is a reliable prognostic factor in various types of gastrointestinal (GI) cancers based on current high-quality multivariable evidence.

Methods

A comprehensive search was conducted in PubMed, Embase, Scopus, and ISI Web of Science databases to investigate the association between Ki-67 positivity and overall survival (OS) and disease/recurrence-free survival (DFS/RFS) in GI cancers. Heterogeneity was assessed using Chi-square-based Q and I2 analyses and publication bias using funnel plots and Egger’s analysis. In addition, Ki-67 levels in different GI cancers were examined by different platforms. The prognostic capability of Ki-67, gene ontology (GO), and pathway enrichment analysis were obtained from GEPIA2 and STRING.

Results

Totally, 61 studies, involving 13,034 patients, were deemed eligible for our evaluation. The combined hazard ratios (HRs) demonstrated the prediction ability of overexpressed Ki-67 for a worse OS (HR: 1.67, P < 0.001; HR: 1.37, P = 0.021) and DFS/RFS (HR: 2.06, P < 0.001) in hepatocellular and pancreatic malignancies, respectively, as confirmed by multi-omics databases. However, similar correlation was not found in esophageal, gastric, and colorectal cancers. Furthermore, most of the associations were identified to be robust based on different subcategories and publication bias assessment. Finally, enriched Ki-67-related genes were found to be involved in various important signaling pathways, such as cell cycle, P53 signaling network, and DNA damage responses.

Conclusion

This study supports that Ki-67 can serve as an independent prognostic biomarker for pancreatic and hepatocellular malignancies in clinical settings.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Nguyen R, Bae SDW, Zhou G, et al. Application of organoids in translational research of human diseases with a particular focus on gastrointestinal cancers. Biochim Biophys Acta Rev Cancer. 2020;1873(2): 188350.CrossRefPubMed
3.
Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(1):335–49.CrossRefPubMed
4.
Aberle MR, Burkhart RA, Tiriac H, et al. Patient-derived organoid models help define personalized management of gastrointestinal cancer. Br J Surg. 2018;105(2):e48–60.CrossRefPubMed
5.
6.
Finkelman BS, Zhang H, Hicks DG, Turner BM. The evolution of Ki-67 and breast carcinoma: past observations, present directions, and future considerations. Cancers (Basel). 2023;15(3):808.PubMedCentralCrossRefPubMed
7.
8.
Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2015;11(3):1566–72.CrossRefPubMed
9.
Xiong DD, Zeng CM, Jiang L, Luo DZ, Chen G. Ki-67/MKI67 as a predictive biomarker for clinical outcome in gastric cancer patients: an updated meta-analysis and systematic review involving 53 studies and 7078 patients. J Cancer. 2019;10(22):5339–54.PubMedCentralCrossRefPubMed
10.
Verhoven B, Yan Y, Ritter M, et al. Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94–08. Int J Radiat Oncol Biol Phys. 2013;86(2):317–23.PubMedCentralCrossRefPubMed
11.
Wu Q, Ma G, Deng Y, et al. Prognostic value of Ki-67 in patients with resected triple-negative breast cancer: a meta-analysis. Front Oncol. 2019;9:1068.PubMedCentralCrossRefPubMed
12.
Luo ZW, Zhu MG, Zhang ZQ, et al. Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis. BMC Cancer. 2019;19(1):123.PubMedCentralCrossRefPubMed
13.
Shi Z, Jiang W, Chen X, et al. Prognostic and clinicopathological value of Ki-67 expression in patients with nasopharyngeal carcinoma: a meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920951346.PubMedCentralCrossRefPubMed
14.
Wei DM, Chen WJ, Meng RM, et al. Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients. Respir Res. 2018;19(1):150.PubMedCentralCrossRefPubMed
15.
Tian Y, Ma Z, Chen Z, et al. Clinicopathological and prognostic value of Ki-67 expression in bladder cancer: a systematic review and meta-analysis. PLoS ONE. 2016;11(7): e0158891.PubMedCentralCrossRefPubMed
16.
Pan DH, Wen DY, Luo YH, et al. The diagnostic and prognostic values of Ki-67/MIB-1 expression in thyroid cancer: a meta-analysis with 6,051 cases. Onco Targets Ther. 2017;10:3261–76.PubMedCentralCrossRefPubMed
17.
Guzinska-Ustymowicz K, Stepien E, Kemona A. MCM-2, Ki-67 and PCNA protein expressions in pT3G2 colorectal cancer indicated lymph node involvement. Anticancer Res. 2008;28(1B):451–7.PubMed
18.
Fasching PA, Heusinger K, Haeberle L, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11:486.PubMedCentralCrossRefPubMed
19.
Wu A, Jia Y, Dong B, et al. Apoptosis and KI 67 index correlate with preoperative chemotherapy efficacy and better predict the survival of gastric cancer patients with combined therapy. Cancer Chemother Pharmacol. 2014;73(5):885–93.CrossRefPubMed
20.
Munn Z, Stern C, Aromataris E, Lockwood C, Jordan Z. What kind of systematic review should I conduct? A proposed typology and guidance for systematic reviewers in the medical and health sciences. BMC Med Res Methodol. 2018;18(1):5.PubMedCentralCrossRefPubMed
21.
Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160.PubMedCentralCrossRefPubMed
22.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed
23.
24.
Gheytanchi E, Tajik F, Razmi M, et al. Circulating exosomal microRNAs as potential prognostic biomarkers in gastrointestinal cancers: a systematic review and meta-analysis. Cancer Cell Int. 2023;23(1):10.PubMedCentralCrossRefPubMed
25.
Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–60.PubMedCentralCrossRefPubMed
26.
27.
Chandrashekar DS, Karthikeyan SK, Korla PK, et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18–27.PubMedCentralCrossRefPubMed
28.
Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome. Protein Sci. 2018;27(1):233–44.CrossRefPubMed
29.
Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards Suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinform. 2016;54(1):3031–313033.CrossRef
30.
Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.PubMedCentralCrossRefPubMed
31.
Kuleshov MV, Jones MR, Rouillard AD, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90-97.PubMedCentralCrossRefPubMed
32.
Bi J, Guo AL, Lai YR, et al. Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays. Neoplasma. 2010;57(3):191–7.CrossRefPubMed
33.
Cai X, Qi WX, Wang L, Zhang Z. Correlation of multiple proteins with clinic-pathological features and its prognostic significance in colorectal cancer with signet-ring cell component. Eur Rev Med Pharmacol Sci. 2016;20(16):3358–67.PubMed
34.
Cao X, Xia Y, Yang J, et al. Clinical and biological significance of never in mitosis gene A-related kinase 6 (NEK6) expression in hepatic cell cancer. Pathol Oncol Res. 2012;18(2):201–7.CrossRefPubMed
35.
Chen HW, Qiao HY, Li HC, et al. Prognostic significance of Nemo-like kinase expression in patients with hepatocellular carcinoma. Tumour Biol. 2015;36(11):8447–53.CrossRefPubMed
36.
Crumley AB, Going JJ, Hilmy M, et al. Interrelationships between tumor proliferative activity, leucocyte and macrophage infiltration, systemic inflammatory response, and survival in patients selected for potentially curative resection for gastroesophageal cancer. Ann Surg Oncol. 2011;18(9):2604–12.CrossRefPubMed
37.
Gayyed MF, Soliman MM, Ahmed MF, et al. Activation of the P38-MSK1 axis in colorectal adenocarcinoma determines a good prognostic outcome. Pol J Pathol. 2021;72(1):39–47.CrossRef
38.
Go SI, Ko GH, Lee WS, et al. The use of CD44 variant 9 and Ki-67 combination can predicts prognosis better than their single use in early gastric cancer. Cancer Res Treat. 2019;51(4):1411–9.PubMedCentralCrossRefPubMed
39.
Dae Hong K, Lee D, Lee Y, Lee SI, Moon HY. Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer. Am Surg. 2013;79(4):353–60.CrossRef
40.
Geng M, Cao YC, Chen YJ, et al. Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis. World J Gastroenterol. 2012;18(12):1328–38.PubMedCentralCrossRefPubMed
41.
Huang JX, Chen WC, Lin M, et al. Clinicopathological significance of cyclooxygenase-2 and cell cycle-regulatory proteins expression in patients with esophageal squamous cell carcinoma. Dis Esophagus. 2012;25(2):121–9.CrossRefPubMed
42.
Liu AW, Cai J, Zhao XL, et al. The clinicopathological significance of BUBR1 overexpression in hepatocellular carcinoma. J Clin Pathol. 2009;62(11):1003–8.CrossRefPubMed
43.
Li D, Yan D, Tang H, et al. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol. 2009;16(12):3499–506.CrossRefPubMed
44.
Kang Y, Jung WY, Lee H, et al. Prognostic significance of heat shock protein 70 expression in early gastric carcinoma. Korean J Pathol. 2013;47(3):219–26.PubMedCentralCrossRefPubMed
45.
Lee C, He H, Jiang Y, et al. Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis. Med Oncol. 2013;30(4):700.CrossRefPubMed
46.
Jiang H, Du J, Jin J, et al. LSF expression and its prognostic implication in colorectal cancer. Int J Clin Exp Pathol. 2014;7(9):6024–31.PubMedCentralPubMed
47.
Murakami K, Kasajima A, Kawagishi N, Ohuchi N, Sasano H. Microvessel density in hepatocellular carcinoma: prognostic significance and review of the previous published work. Hepatol Res. 2015;45(12):1185–94.CrossRefPubMed
48.
Nishiwada S, Sho M, Yasuda S, et al. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res. 2015;34(1):30.PubMedCentralCrossRefPubMed
49.
Li X, Xiao Y, Fan S, et al. Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma. Hum Pathol. 2016;57:182–92.CrossRefPubMed
50.
Ko GH, Go SI, Lee WS, et al. Prognostic impact of Ki-67 in patients with gastric cancer-the importance of depth of invasion and histologic differentiation. Medicine (Baltimore). 2017;96(25): e7181.CrossRefPubMed
51.
Li C, Wu M, Zong G, et al. Overexpression of protein phosphatase 1gamma (PP1gamma) is associated with enhanced cell proliferation and poor prognosis in hepatocellular carcinoma. Dig Dis Sci. 2017;62(1):133–42.CrossRefPubMed
52.
Li M, Ke J, Wang Q, et al. Upregulation of ROCK2 in gastric cancer cell promotes tumor cell proliferation, metastasis and invasion. Clin Exp Med. 2017;17(4):519–29.CrossRefPubMed
53.
Liu D, Sun L, Tong J, et al. Prognostic significance of glutathione peroxidase 2 in gastric carcinoma. Tumour Biol. 2017;39(6):1010428317701443.CrossRefPubMed
54.
Li HH, Qi LN, Ma L, et al. Effect of KI-67 positive cellular index on prognosis after hepatectomy in Barcelona Clinic Liver Cancer stage A and B hepatocellular carcinoma with microvascular invasion. Onco Targets Ther. 2018;11:4747–54.PubMedCentralCrossRefPubMed
55.
Jiao D, Li Y, Yang F, et al. Expression of prostate-specific membrane antigen in tumor-associated vasculature predicts poor prognosis in hepatocellular carcinoma. Clin Transl Gastroenterol. 2019;10(5):1–7.CrossRefPubMed
56.
Vireak C, Seo AN, Han MH, et al. Aquaporin 5 expression correlates with tumor multiplicity and vascular invasion in hepatocellular carcinoma. Int J Clin Exp Pathol. 2019;12(2):516–27.PubMedCentralPubMed
57.
Redondo M, Abitei C, Tellez T, et al. Clinical-pathological characteristics and short-term follow-up associated with proliferation, apoptosis and angiogenesis in a prospective cohort of patients with colorectal tumours. Tumour Biol. 2019;42(4):1010428319835684.PubMed
58.
59.
Xiao LJ, Zhao S, Zhao EH, et al. Clinicopathological and prognostic significance of Ki-67, caspase-3 and p53 expression in gastric carcinomas. Oncol Lett. 2013;6(5):1277–84.PubMedCentralCrossRefPubMed
60.
Xi HQ, Zhao P. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol. 2011;64(6):498–503.CrossRefPubMed
61.
Qin R, Smyrk TC, Reed NR, et al. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1alpha pathway to predict survival in resectable pancreatic cancer. Br J Cancer. 2015;112(3):514–22.PubMedCentralCrossRefPubMed
62.
Peng Y, Wang L, Gu J. Elevated preoperative carcinoembryonic antigen (CEA) and Ki67 is predictor of decreased survival in IIA stage colon cancer. World J Surg. 2013;37(1):208–13.CrossRefPubMed
63.
Wei Z, Huang L, Zhang X, Xu A. Expression and significance of Her2 and Ki-67 in gastric adenocarcinoma without distant metastasis: a cohort study. BMC Gastroenterol. 2020;20(1):343.PubMedCentralCrossRefPubMed
64.
Shi W, Hu J, Zhu S, Shen X, Zhang X, Yang C, Gao H, Zhang H. Expression of MTA2 and Ki-67 in hepatocellular carcinoma and their correlation with prognosis. Int J Clin Exp Pathol. 2015;8(10):13083–9.PubMedCentralPubMed
65.
Srivastava S, Thakkar B, Yeoh KG, et al. Expression of proteins associated with hypoxia and Wnt pathway activation is of prognostic significance in hepatocellular carcinoma. Virchows Arch. 2015;466(5):541–8.CrossRefPubMed
66.
Ye F, Jin P, Cai X, Cai P, Cai H. High RNA-binding motif protein 3 (RBM3) expression is independently associated with prolonged overall survival in intestinal-type gastric cancer. Med Sci Monit. 2017;23:6033–41.PubMedCentralCrossRefPubMed
67.
Ohtani M, Isozaki H, Fujii K, Nomura E, Niki M, Mabuchi H, Nishiguchi K, Toyoda M, Ishibashi T, Tanigawa N. Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients with non–early stage gastric carcinoma. Cancer. 1999;85(8):1711–8.CrossRefPubMed
68.
Zhang Z, Wang M, Zhou L, et al. Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer. J Exp Clin Cancer Res. 2015;34(1):51.PubMedCentralCrossRefPubMed
69.
Jean-Christophe Weber HN, Philippe Bachellier,, Elie Oussoultzoglou KI, Hiroshi Shimura, Philippe Wolf, Marie-Pierre Chenard-Neu, Daniel Jaeck. Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am J Surg. 2001;182(1):81–8.
70.
Ming-Hai Wang S-YQ, Shu-Guang Zhang, Guang-Xin Li, Zhen-Hai Yu, Kun Wang, Bin Wang, Mu-Jian Teng, Zhi-Hai Peng. Musashi-2 promotes hepatitis B virus related hepatocellular carcinoma progression via the Wnt/β-catenin pathway. Am J Cancer Res. 2015;5(3):1089–100.
71.
Sun L, Guo C, Cao J, et al. Over-expression of alpha-enolase as a prognostic biomarker in patients with pancreatic cancer. Int J Med Sci. 2017;14(7):655–61.PubMedCentralCrossRefPubMed
72.
Wang SN, Chuang SC, Yeh YT, et al. Potential prognostic value of leptin receptor in hepatocellular carcinoma. J Clin Pathol. 2006;59(12):1267–71.PubMedCentralCrossRefPubMed
73.
Shinji Yamamoto YT, Yoshihiko Hoshida, Takaya Morooka, Hiroaki Nagano, Keizo Dono, Koji Umeshita, Masato Sakon, Osamu Ishikawa, Hiroaki Ohigashi, Shoji Nakamori, Morito Monden, Katsuyuki Aozasa. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;10(8):2846–50.
74.
Tzanakis NE, Peros G, Karakitsos P, et al. Prognostic significance of p53 and Ki67 proteins expression in Greek gastric cancer patients. Acta Chir Belg. 2009;109(5):606–11.CrossRefPubMed
75.
Wang L, Liu Z, Fisher KW, et al. Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer. Hum Pathol. 2018;71:20–9.CrossRefPubMed
76.
Teraoku H, Morine Y, Ikemoto T, et al. Role of thrombospondin-1 expression in colorectal liver metastasis and its molecular mechanism. J Hepatobiliary Pancreat Sci. 2016;23(9):565–73.CrossRefPubMed
77.
Shin IY, Sung NY, Lee YS, et al. The expression of multiple proteins as prognostic factors in colorectal cancer: cathepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67. Gut Liver. 2014;8(1):13–23.CrossRefPubMed
78.
ATHANASSIOS C. TSAMANDAS DK, PANTELIS TSIAMALOS, ANNA LIAVA1, VASSILIKI TZELEPI, VASSILIOS VASSILIOU, THEODORE PETSAS, KONSTANTINOS VAGENAS, VASSILIKI ZOLOTA, CHRISOULA D. SCOPA. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome. Anticancer Res. 2009;29(2):703–9.
79.
Wei X, Bu J, Mo X, et al. The prognostic significance of FBXO2 expression in colorectal cancer. Int J Clin Exp Pathol. 2018;11(10):5054–62.PubMedCentralPubMed
80.
Xu P, Zhang X, Ni W, et al. Upregulated HOXC8 expression is associated with poor prognosis and oxaliplatin resistance in hepatocellular carcinoma. Dig Dis Sci. 2015;60(11):3351–63.CrossRefPubMed
81.
Wang Q, Li M, Zhang X, et al. Upregulation of CDK7 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis. Exp Mol Pathol. 2016;100(3):514–21.CrossRefPubMed
82.
Yang X, Ni H, Lu Z, et al. Mesenchymal circulating tumor cells and Ki67: their mutual correlation and prognostic implications in hepatocellular carcinoma. BMC Cancer. 2023;23(1):10.PubMedCentralCrossRefPubMed
83.
Lei HT, Yan S, He YH, et al. Ki67 testing in the clinical management of patients with non-metastatic colorectal cancer: detecting the optimal cut-off value based on the restricted cubic spline model. Oncol Lett. 2022;24(6):420.PubMedCentralCrossRefPubMed
84.
Piao J, Liu S, Xu Y, et al. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas. Exp Mol Pathol. 2015;98(1):1–6.CrossRefPubMed
85.
Yanagisawa N, Ichinoe M, Mikami T, et al. High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas. J Clin Pathol. 2012;65(11):1019–23.CrossRefPubMed
86.
Kaira K, Sunose Y, Arakawa K, et al. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer. 2012;107(4):632–8.PubMedCentralCrossRefPubMed
87.
Melling N, Kowitz CM, Simon R, et al. High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol. 2016;69(3):209–14.CrossRefPubMed
88.
Tong G, Zhang G, Liu J, et al. Cutoff of 25% for Ki67 expression is a good classification tool for prognosis in colorectal cancer in the AJCC-8 stratification. Oncol Rep. 2020;43(4):1187–98.PubMedCentralPubMed
89.
C. Y. Wu ZRH, Chen RP, Lin, WP. Expression of Ki-67 protein in adenocarcinoma of esophagogastric junction and its correlation with clinicopathological features and prognosis. Indian J Pharm Sci. 2020;82(2) Spl issue 3;127–34.
90.
Wang B, Li M, Su A, et al. Prognostic value of GPNMB, EGFR, p-PI3K, and Ki-67 in patients with esophageal squamous cell carcinoma. Anal Cell Pathol (Amst). 2022;2022:9303081.PubMed
91.
Fluge O, Gravdal K, Carlsen E, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer. 2009;101(8):1282–9.PubMedCentralCrossRefPubMed
92.
93.
Seo SH, Kim KH, Oh SH, et al. Ki-67 labeling index as a prognostic marker in advanced stomach cancer. Ann Surg Treat Res. 2019;96(1):27–33.CrossRefPubMed
94.
Luo Y, Ren F, Liu Y, et al. Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis. Int J Clin Exp Med. 2015;8(7):10235–47.PubMedCentralPubMed
95.
Han S, Huang T, Li W, et al. Prognostic value of CD44 and its isoforms in advanced cancer: a systematic meta-analysis with trial sequential analysis. Front Oncol. 2019;9:39.PubMedCentralCrossRefPubMed
96.
97.
Naheed S, Holden C, Tanno L, et al. Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis. BMJ Open. 2022;12(3): e041961.PubMedCentralCrossRefPubMed
98.
Martins SF, Amorim R, Mota SC, et al. Ki-67 Expression in CRC lymph node metastasis does not predict survival. Biomed Res Int. 2015;2015: 131685.PubMedCentralCrossRefPubMed
99.
100.
Sobecki M, Mrouj K, Colinge J, et al. Cell-cycle regulation accounts for variability in Ki-67 expression levels. Cancer Res. 2017;77(10):2722–34.CrossRefPubMed
101.
102.
Liu M, Lin C, Huang Q, et al. SRSF3-Mediated Ki67 exon 7-inclusion promotes head and neck squamous cell carcinoma progression via repressing AKR1C2. Int J Mol Sci. 2023;24(4):3872.PubMedCentralCrossRefPubMed
103.
Cidado J, Wong HY, Rosen DM, et al. Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget. 2016;7(5):6281–93.PubMedCentralCrossRefPubMed
104.
Metadaten
Titel
The Prognostic Importance of Ki-67 in Gastrointestinal Carcinomas: A Meta-analysis and Multi-omics Approach
verfasst von
Mahdieh Razmi
Fatemeh Tajik
Farideh Hashemi
Ayna Yazdanpanah
Fatemeh Hashemi-Niasari
Adeleh Divsalar
Publikationsdatum
27.02.2024
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 2/2024
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-024-01022-w

Weitere Artikel der Ausgabe 2/2024

Short-Term Safety Evaluation of Albumin-Bound Paclitaxel in Intraoperative and Postoperative Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer

  • Research

Laparoscopic Versus Open Gastrectomy for Advanced Gastric Cancer: A Meta-Analysis of Randomized Controlled Trials

  • Review

Regional Therapy Approaches for Gastric Cancer with Limited Peritoneal Disease

  • Open Access
  • Review

Atezolizumab and Bevacizumab Targeted-Therapy in Advanced Hepatocellular Carcinoma: A Systematic Review of Cost-effectiveness Analyses

  • Review

Association of Methylenetetrahydrofolate Reductase rs1801133 Gene Polymorphism with Cancer Risk and Septin 9 Methylation in Patients with Colorectal Cancer

  • Open Access
  • Research

PD-L1 Expression in Colorectal Carcinoma Correlates with the Immune Microenvironment

  • Research

Neu im Fachgebiet Onkologie

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Cannabisextrakt verbessert Antiemese bei Chemotherapie

Sprechen Krebskranke auf die übliche Antiemese während einer Chemotherapie nicht ausreichend an, lohnt sich möglicherweise eine Behandlung mit Cannabisextrakt. In einer Phase-2/3-Studie ließ sich die antiemetische Response mit einem solchen Extrakt erheblich verbessern.

Veränderung der Brustdichte beeinflusst das Krebsrisiko

Die radiologische Dichte des Mammagewebes ist mit dem Risiko assoziiert, an Brustkrebs zu erkranken. Dabei wirken sich laut Ergebnissen einer Studie auch Dichteänderungen aus. Fünf Verlaufsmuster lassen sich dabei unterscheiden.

PMBCL mit CMR: Radiatio kann ohne Risiko weggelassen werden

Patienten mit primär mediastinalem B-Zell-Lymphom (PMBCL), die nach der Induktionstherapie eine komplette metabolische Remission (CMR) erreichen und keine konsolidierende Bestrahlung erhalten, müssen offenbar keine Überlebensnachteile fürchten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise